BLLN

ANALYST NOTE: BLLN (BillionToOne, Inc.) Date: 2026-06-20 Current Price: $105.15

1. Structural Readiness

Breakout Level: Not yet defined (requires confirmation of the specific structural high that defines the coil top) Current Price: $105.15 Extension: Not yet defined (price is currently within the forming range, not extended above the breakout level)

2. Thesis Layer

Primary Secular Thesis: Biotech & GLP-1 → Diagnostics (Tier Direct) Thesis Strength: High Confidence

BillionToOne is a direct beneficiary of the secular shift toward precision molecular diagnostics, specifically within the prenatal and oncology sectors. The company's single-molecule next-generation sequencing (smNGS) platform addresses the critical need for ultrasensitive detection of cell-free DNA (cfDNA).

• Prenatal Tailwind: The company is capitalizing on the rapid adoption of non-invasive prenatal testing (NIPT), now testing approximately 1 in 11 babies in the U.S. The recent launch of fetal antigen test products and the expansion of network coverage (Anthem partnership) directly accelerate this secular trend.
• Oncology Tailwind: The transition from early-stage liquid biopsy to Minimal Residual Disease (MRD) detection represents a massive expansion of the addressable market. The company is positioned to capture value as oncologists increasingly demand tools for therapy selection and response monitoring.

The company is not merely a participant but a primary architect of the "tissue-free" diagnostic paradigm, leveraging its proprietary smNGS technology to solve unmet needs in both maternal-fetal medicine and cancer care.

3. Business Overview

Business Model: BillionToOne operates a high-margin, volume-driven molecular diagnostics business. It generates revenue by processing clinical samples (tests accessioned) using its proprietary smNGS platform. The company sells tests directly to healthcare providers and laboratories, with reimbursement driven by commercial insurance and Medicare coverage.

Key Operational Metrics (as of Q1 2026):

• Revenue Growth: The company reported Q1 2026 revenue of $108.4 million (implied from $49.4M increase vs prior year), representing an 84% year-over-year increase.
• Volume Growth: Total test volume grew to approximately 189,000 tests in Q1 2026, up from 137,000 in the prior year period.
• *Prenatal:* Volumes grew 10% sequentially, with Q1 revenue reaching $97.7 million (up 72% YoY).
• *Oncology:* Volumes grew 25% sequentially, with Q1 revenue reaching $10.7 million (nearly 5x YoY), establishing an annualized run rate of $43 million.
• Market Penetration: The company has secured network status with Anthem, bringing total contracted lives to approximately 300 million in the U.S., covering over 90% of patients.
• Technology & Capacity: The company has processed over 1 million smNGS-based tests since launch, with 676,000 (45%) processed in the last 12 months. Management expects to occupy a new facility in 2027, with commercial processing opening in 2028, which will triple current testing capacity.

Financial Quality:

• Gross Margins: Gross margins expanded to 73% in Q1 2026 from 64% in the prior year period. Management expects to maintain gross margins above 70% for the full year.
• Guidance: Management raised full-year 2026 revenue guidance to a range of $445 million to $465 million, implying 48% to 52% growth compared to 2025.

4. Archetype and Conviction

Archetype: Margin Inflector / Growth Leader

BillionToOne fits the Margin Inflector archetype. The company has successfully transitioned from a pure growth story to one demonstrating significant operating leverage and margin expansion. The gross margin expansion from 64% to 73% in a single quarter, while scaling revenue by 84%, indicates that the smNGS platform is achieving economies of scale and operational efficiency.

Conviction Stack:

• Thesis Strength: High. The secular demand for cfDNA testing in prenatal and oncology is robust and accelerating.
• Evidence Quality: Strong. The evidence base (E1-E23) provides concrete, quantitative proof of volume growth, margin expansion, and strategic partnerships (Anthem, J&J).
• Structural Quality: The company is executing on its roadmap, with the MRD launch on track for late 2026 and a clear path to capacity expansion in 2027-2028.
• Rerating Potential: Significant. As the company moves from "growth at all costs" to "profitable growth with expanding margins," and as the MRD product launches, the market may re-rate the stock from a pure biotech growth name to a high-margin diagnostic leader.

5. Invalidation, Strengthening, and Gaps

What Would Invalidate:

• Fundamental: A significant miss on the 2026 revenue guidance (e.g., guidance cut below $445M) or a failure to launch the MRD test by the end of 2026 as stated in management expectations.
• Operational: A reversal in gross margin trends (e.g., margins dropping below 70%) due to pricing pressure or increased cost of goods sold.

What Would Strengthen:

• Technical: A confirmed breakout above the coil's resistance level with volume expansion.
• Fundamental: Confirmation of the MRD launch with early commercial traction or additional payer network expansions beyond Anthem.
• Operational: Further margin expansion beyond 73% or acceleration in oncology volume growth rates.

Gaps in Evidence:

• Profitability: While gross margins are strong, the evidence does not explicitly state the company's net income or EBITDA status as of Q1 2026. The path to sustained net profitability is implied by the margin inflector archetype but not explicitly quantified in the provided evidence.
• MRD Clinical Data: While the MRD launch is "on track," the specific clinical data supporting the launch (E3) is expected to be released *at* the time of launch. The quality of the data and its impact on adoption remains a forward-looking variable not yet fully realized in the evidence base.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: High Key evidence: 1) Q1 2026 revenue grew 84% YoY to ~$108M with gross margins expanding to 73%. 2) Management raised full-year 2026 revenue guidance to $445M-$465M (48-52% growth). 3) Strategic network expansion with Anthem covers 90% of U.S. patients, and MRD launch is on track for late 2026. Sizing hint: Position size should be calibrated to the "forming" status; consider a partial entry on the current structure with a plan to add on confirmed breakout, or wait for the breakout to confirm the trend. Expected path: Management expects MRD launch by end of 2026, followed by facility occupancy in 2027 and full capacity utilization in 2028. Revenue growth is expected to remain in the high 40s to low 50s percentage range for 2026. Expected horizon: 6 to 12 months for the MRD launch catalyst to fully price in, with structural capacity expansion playing out over 24 months.